Tags

Type your tag names separated by a space and hit enter

Rituximab for Treatment of Refractory Anti-NMDA Receptor Encephalitis in a Pediatric Patient.
J Pediatr Pharmacol Ther. 2017 Mar-Apr; 22(2):118-123.JP

Abstract

Anti-N-methyl d-aspartate receptor (anti-NMDAR) encephalitis is a devastating disease that is increasingly being identified in both children and adults with psychosis, language disturbances, behavioral changes, and motor deficits. Currently no consensus guidelines exist for the optimal management of patients with this disease, although intravenous immune globulin (IVIG) therapy is often considered first-line pharmacotherapy. We present a case of an otherwise healthy 4 year-old-child who presented with seizures, loss of age-appropriate language skills, and behavioral changes, in whom anti-NMDAR was subsequently diagnosed. After marked intolerance to corticosteroid therapy and inadequate clinical response to IVIG, immunotherapy with rituximab was initiated. The patient had rapid return of language skills and complete resolution of dyskinesia after a single rituximab infusion, with no residual deficits at her 6-month follow-up visit. Early intervention in patients with anti-NMDAR encephalitis is of paramount importance for successful outcomes and baseline recovery. Only approximately half of patients respond to first-line immunotherapy, necessitating further evaluation of alternative therapies and the development of a treatment algorithm for practitioners. This case report builds upon previous findings illustrating rapid symptom resolution after rituximab infusion and adds to the available body of evidence for management of pediatric patients with anti-NMDAR.

Authors

No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Case Reports

Language

eng

PubMed ID

28469537

Citation

Hallowell, Sarah, et al. "Rituximab for Treatment of Refractory Anti-NMDA Receptor Encephalitis in a Pediatric Patient." The Journal of Pediatric Pharmacology and Therapeutics : JPPT : the Official Journal of PPAG, vol. 22, no. 2, 2017, pp. 118-123.
Hallowell S, Tebedge E, Oates M, et al. Rituximab for Treatment of Refractory Anti-NMDA Receptor Encephalitis in a Pediatric Patient. The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG. 2017;22(2):118-123.
Hallowell, S., Tebedge, E., Oates, M., & Hand, E. (2017). Rituximab for Treatment of Refractory Anti-NMDA Receptor Encephalitis in a Pediatric Patient. The Journal of Pediatric Pharmacology and Therapeutics : JPPT : the Official Journal of PPAG, 22(2), 118-123. https://doi.org/10.5863/1551-6776-22.2.118
Hallowell S, et al. Rituximab for Treatment of Refractory Anti-NMDA Receptor Encephalitis in a Pediatric Patient. The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG. 2017 Mar-Apr;22(2):118-123. PubMed PMID: 28469537.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Rituximab for Treatment of Refractory Anti-NMDA Receptor Encephalitis in a Pediatric Patient. AU - Hallowell,Sarah, AU - Tebedge,Esli, AU - Oates,Margaret, AU - Hand,Elizabeth, PY - 2017/5/5/entrez PY - 2017/5/5/pubmed PY - 2017/5/5/medline KW - anti-N-methyl d-aspartate receptor KW - anti-N-methyl d-aspartate receptor encephalitis KW - anti-NMDAR KW - case report KW - pediatric KW - rituximab SP - 118 EP - 123 JF - The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG VL - 22 IS - 2 N2 - Anti-N-methyl d-aspartate receptor (anti-NMDAR) encephalitis is a devastating disease that is increasingly being identified in both children and adults with psychosis, language disturbances, behavioral changes, and motor deficits. Currently no consensus guidelines exist for the optimal management of patients with this disease, although intravenous immune globulin (IVIG) therapy is often considered first-line pharmacotherapy. We present a case of an otherwise healthy 4 year-old-child who presented with seizures, loss of age-appropriate language skills, and behavioral changes, in whom anti-NMDAR was subsequently diagnosed. After marked intolerance to corticosteroid therapy and inadequate clinical response to IVIG, immunotherapy with rituximab was initiated. The patient had rapid return of language skills and complete resolution of dyskinesia after a single rituximab infusion, with no residual deficits at her 6-month follow-up visit. Early intervention in patients with anti-NMDAR encephalitis is of paramount importance for successful outcomes and baseline recovery. Only approximately half of patients respond to first-line immunotherapy, necessitating further evaluation of alternative therapies and the development of a treatment algorithm for practitioners. This case report builds upon previous findings illustrating rapid symptom resolution after rituximab infusion and adds to the available body of evidence for management of pediatric patients with anti-NMDAR. SN - 1551-6776 UR - https://www.unboundmedicine.com/medline/citation/28469537/Rituximab_for_Treatment_of_Refractory_Anti_NMDA_Receptor_Encephalitis_in_a_Pediatric_Patient_ L2 - https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/28469537/ DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.